Literature DB >> 7307234

The combination of melphalan with prednisolone. Anti-tumor effect and normal tissue toxicity in laboratory systems.

P J Selby, J L Millar, T A Phelps, M Y Gordon, R Wilkinson, T J McElwain.   

Abstract

The effect of prednisolone upon the therapeutic index of melphalan has been studied in a variety of laboratory systems. The anti-tumour action of melphalan was assessed for a human melanoma xenograft growing in immune-deprived mice, clonogenic cell survival and tumour growth delay being used as end-points. Normal tissue toxicity was assessed for human bone marrow colony-forming units, murine bone marrow colony-forming units, murine gastrointestinal crypt microcolony-forming cells, and mouse survival. Prednisolone had no anti-tumour effect when given alone, but increased the anti-tumour effect of melphalan significantly. No increase in the toxicity of melphalan to marrow or gut colony-forming cells could be demonstrated. However, mouse survival was significantly lower after treatment with the combination than with melphalan alone. This study supports the view that steroids may enhance the anti-tumour effect of some alkylating agents, but this may be at the expense of increased normal tissue toxicity in some circumstances.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7307234     DOI: 10.1007/bf00262338

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  23 in total

1.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.

Authors:  J E TILL; E A McCULLOCH
Journal:  Radiat Res       Date:  1961-02       Impact factor: 2.841

2.  Specific regulation by steroid hormones of the amount of type I cyclic AMP-dependent protein kinase holoenzyme.

Authors:  D J Fuller; C V Byus; D H Russell
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

3.  Cyclic nucleotide metabolism in Walker carcinoma cells resistant to alkylating agents.

Authors:  M J Tisdale; B J Phillips
Journal:  Biochem Pharmacol       Date:  1978-03-15       Impact factor: 5.858

4.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

5.  Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.

Authors:  R Alexanian; A Haut; A U Khan; M Lane; E M McKelvey; P J Migliore; W J Stuckey; H E Wilson
Journal:  JAMA       Date:  1969-06-02       Impact factor: 56.272

6.  Enhanced post-irradiation recovery of the haemopoietic system in animals pretreated with a variety of cytotoxic agents.

Authors:  J L Millar; N M Blackett; B N Hudspith
Journal:  Cell Tissue Kinet       Date:  1978-09

7.  Distribution and metabolism of prednisone in mice, dogs, and monkeys.

Authors:  S M El Dareer; R F Struck; V M White; L B Mellett; D L Hill
Journal:  Cancer Treat Rep       Date:  1977-10

8.  Improved immune-suppression techniques for the exongrafting of human tumours.

Authors:  G G Steel; V D Courtenay; A Y Rostom
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

9.  Human tumour xenografts established and serially transplanted in mice immunologically deprived by thymectomy, cytosine arabinoside and whole-body irradiation.

Authors:  P J Selby; J M Thomas; P Monaghan; J Sloane; M J Peckham
Journal:  Br J Cancer       Date:  1980-01       Impact factor: 7.640

10.  Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.

Authors:  T J McElwain; D W Hedley; G Burton; H M Clink; M Y Gordon; M Jarman; C A Juttner; J L Millar; R A Milsted; G Prentice; I E Smith; D Spence; M Woods
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.